Literature DB >> 18514351

In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting.

Marilyn Martinez1, Michael Rathbone, Diane Burgess, Mai Huynh.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18514351     DOI： 10.1016/j.jconrel.2008.04.004

Source DB:  PubMed          Journal:  J Control Release        ISSN： 0168-3659            Impact factor:   9.776


× No keyword cloud information.
  13 in total

Review 1.  Points to consider when establishing drug product specifications for parenteral microspheres.

Authors:  Rajesh Kumar; Michael J Palmieri
Journal:  AAPS J       Date:  2009-11-17       Impact factor: 4.009

Review 2.  Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.

Authors:  Susan Weng Larsen; Claus Larsen
Journal:  AAPS J       Date:  2009-11-06       Impact factor: 4.009

3.  FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.

Authors:  Cynthia K Brown; Horst Dieter Friedel; Amy R Barker; Lucinda F Buhse; Susanne Keitel; Todd L Cecil; Johannes Kraemer; J Michael Morris; Christos Reppas; Mary P Stickelmeyer; Chikako Yomota; Vinod P Shah
Journal:  AAPS PharmSciTech       Date:  2011-06-18       Impact factor: 3.246

4.  In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.

Authors:  Jie Shen; Stephanie Choi; Wen Qu; Yan Wang; Diane J Burgess
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

Review 5.  Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.

Authors:  Jie Shen; Diane J Burgess
Journal:  J Pharm Pharmacol       Date:  2012-03-08       Impact factor: 3.765

Review 6.  Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction.

Authors:  Wei Chen; Bryant C Yung; Zhiyong Qian; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

7.  Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.

Authors:  David P McDonnell; Holland C Detke; Richard F Bergstrom; Prajakti Kothare; Jason Johnson; Mary Stickelmeyer; Manuel V Sanchez-Felix; Sebastian Sorsaburu; Malcolm I Mitchell
Journal:  BMC Psychiatry       Date:  2010-06-10       Impact factor: 3.630

8.  A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.

Authors:  Mahadevabharath R Somayaji; Debarun Das; Andrzej Przekwas
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

9.  In Vitro Dissolution Testing Strategies for Nanoparticulate Drug Delivery Systems: Recent Developments and Challenges.

Authors:  Jie Shen; Diane J Burgess
Journal:  Drug Deliv Transl Res       Date:  2013-10-01       Impact factor: 4.617

10.  Controlled Drug Delivery: Historical perspective for the next generation.

Authors:  Yeon Hee Yun; Byung Kook Lee; Kinam Park
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.